Approach & Pipeline
First generation inflammasome inhibitors are primarily focused on only one (NLRP3) out of seven different receptors (e.g. NLRP1, AIM2, Pyrin etc.) that are involved in the activation and formation of separate inflammasomes. While the single receptor approach is expected to be effective for certain NLRP3 specific diseases, increasingly, research shows that many inflammatory diseases involve more than one type of inflammasome. These diseases where multiple receptors are involved, such as Adult-Onset Still’s Disease (AOSD), Still’s Disease, osteoarthritis, non-alcoholic steatohepatitis (NASH)) and many neuro-inflammatory diseases (e.g. Alzheimer’s and Parkinson’s), may not be effectively controlled by the inhibition of just the one NLRP3 receptor. Thus, to address the unmet opportunity to target multi-receptor diseases, IMMvention has developed a strategy and platform to discover small molecules that target all inflammasomes. With this differentiated strategy the Company has developed several preclinical programs with novel first-in-class small molecules that inhibit multiple inflammasome receptors.
IMMvention is progressing a pipeline of programs towards clinical development.